Potential new antifungal agents

Andreas H. Groll, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

The increasing incidence of both mucosal and invasive fungal infections has led to the development of several new systemic antifungal agents. Potent and broad spectrum, third generation triazoles, echinocandins and pneumocandins, fungicidal inhibitors of 1,3-beta glucan synthase, and a liposomal formulation of nystatin have recently entered early clinical trials. Other promising agents with novel targets currently under investigation include the pradimicin family of antibiotics, nikkomycin Z, and perhaps, antimicrobial peptides. Immunomodulation by recombinant cytokines has been extensively studied in the laboratory, and effective antifungal vaccines are on the horizon. In conjuction with currently available agents, including the lipid formulations of amphotericin B, this expanded antifungal armamentarium holds promise to meet the evolving challenges of both invasive and mucosal fungal infections.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalCurrent Opinion in Infectious Diseases
Volume10
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

Echinocandins
Antifungal Agents
Nystatin
Triazoles
Immunomodulation
Amphotericin B
Vaccines
Clinical Trials
Cytokines
Anti-Bacterial Agents
Lipids
Peptides
Incidence
Invasive Fungal Infections
nikkomycin
1,3-beta-glucan synthase

ASJC Scopus subject areas

  • Immunology
  • Microbiology (medical)

Cite this

Groll, A. H., & Walsh, T. J. (1997). Potential new antifungal agents. Current Opinion in Infectious Diseases, 10(6), 449-458.

Potential new antifungal agents. / Groll, Andreas H.; Walsh, Thomas J.

In: Current Opinion in Infectious Diseases, Vol. 10, No. 6, 1997, p. 449-458.

Research output: Contribution to journalArticle

Groll, AH & Walsh, TJ 1997, 'Potential new antifungal agents', Current Opinion in Infectious Diseases, vol. 10, no. 6, pp. 449-458.
Groll, Andreas H. ; Walsh, Thomas J. / Potential new antifungal agents. In: Current Opinion in Infectious Diseases. 1997 ; Vol. 10, No. 6. pp. 449-458.
@article{04464166eb2940219ea65de247babe91,
title = "Potential new antifungal agents",
abstract = "The increasing incidence of both mucosal and invasive fungal infections has led to the development of several new systemic antifungal agents. Potent and broad spectrum, third generation triazoles, echinocandins and pneumocandins, fungicidal inhibitors of 1,3-beta glucan synthase, and a liposomal formulation of nystatin have recently entered early clinical trials. Other promising agents with novel targets currently under investigation include the pradimicin family of antibiotics, nikkomycin Z, and perhaps, antimicrobial peptides. Immunomodulation by recombinant cytokines has been extensively studied in the laboratory, and effective antifungal vaccines are on the horizon. In conjuction with currently available agents, including the lipid formulations of amphotericin B, this expanded antifungal armamentarium holds promise to meet the evolving challenges of both invasive and mucosal fungal infections.",
author = "Groll, {Andreas H.} and Walsh, {Thomas J.}",
year = "1997",
language = "English (US)",
volume = "10",
pages = "449--458",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Potential new antifungal agents

AU - Groll, Andreas H.

AU - Walsh, Thomas J.

PY - 1997

Y1 - 1997

N2 - The increasing incidence of both mucosal and invasive fungal infections has led to the development of several new systemic antifungal agents. Potent and broad spectrum, third generation triazoles, echinocandins and pneumocandins, fungicidal inhibitors of 1,3-beta glucan synthase, and a liposomal formulation of nystatin have recently entered early clinical trials. Other promising agents with novel targets currently under investigation include the pradimicin family of antibiotics, nikkomycin Z, and perhaps, antimicrobial peptides. Immunomodulation by recombinant cytokines has been extensively studied in the laboratory, and effective antifungal vaccines are on the horizon. In conjuction with currently available agents, including the lipid formulations of amphotericin B, this expanded antifungal armamentarium holds promise to meet the evolving challenges of both invasive and mucosal fungal infections.

AB - The increasing incidence of both mucosal and invasive fungal infections has led to the development of several new systemic antifungal agents. Potent and broad spectrum, third generation triazoles, echinocandins and pneumocandins, fungicidal inhibitors of 1,3-beta glucan synthase, and a liposomal formulation of nystatin have recently entered early clinical trials. Other promising agents with novel targets currently under investigation include the pradimicin family of antibiotics, nikkomycin Z, and perhaps, antimicrobial peptides. Immunomodulation by recombinant cytokines has been extensively studied in the laboratory, and effective antifungal vaccines are on the horizon. In conjuction with currently available agents, including the lipid formulations of amphotericin B, this expanded antifungal armamentarium holds promise to meet the evolving challenges of both invasive and mucosal fungal infections.

UR - http://www.scopus.com/inward/record.url?scp=0030733419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030733419&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030733419

VL - 10

SP - 449

EP - 458

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 6

ER -